Novel SARS-CoV-2 therapeutic targets: RNA proofreading complex and virus-induced senescence

COVID-19 vaccines: where we stand and challenges ahead

(2021) Guido Forni et al.   CELL DEATH AND DIFFERENTIATION

Virus-induced senescence is driver and therapeutic target in COVID-19

(2021) Soyoung Lee et al.   NATURE

The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target

(2021) Gergely Rona et al.   CELL DEATH AND DIFFERENTIATION

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

COVID-19 infection: the perspectives on immune responses

(2020) Yufang Shi et al.   CELL DEATH AND DIFFERENTIATION

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

(2020) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

An aberrant STAT pathway is central to COVID-19

(2020) Toshifumi Matsuyama et al.   CELL DEATH AND DIFFERENTIATION

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

(2020) Fran Robson et al.   MOLECULAR CELL

The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold

(2018) Katherine L. Seley-Radtke et al.   ANTIVIRAL RESEARCH

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

(2018) Maria L. Agostini et al.   mBio

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

(2017) François Ferron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA